	US 12,460,008 B2
	Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
Pingxia Zhu, Beijing (CN); Ran Wu, Beijing (CN); Qingshuang Zhang, Beijing (CN); and Qun Huang, Beijing (CN)
Assigned to STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD., Beijing (CN)
Appl. No. 17/297,421
Filed by STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD., Beijing (CN)
PCT Filed Nov. 25, 2019, PCT No. PCT/CN2019/120545 § 371(c)(1), (2) Date May 26, 2021, PCT Pub. No. WO2020/108423, PCT Pub. Date Jun. 4, 2020.
Claims priority of application No. PCT/CN2018/117581 (WO), filed on Nov. 27, 2018.
Prior Publication US 2023/0002496 A1, Jan. 5, 2023
Int. Cl. C07K 16/28 (2006.01); C12N 15/79 (2006.01)

CPC C07K 16/2866 (2013.01) [C12N 15/79 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

15 Claims

1. An isolated anti-GM-CSFRα antibody, comprising: a V_Hcomprising an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-4; an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 6-16; and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 17-50; and a V_Lcomprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51; an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 52; and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 53-61, or 63-75.